"The goal is to expand treatment options for HER2-mutant NSCLC, which is currently a challenging and prognostically unfavourable mutation," according to Wolfgang Brueckl, MD, of t ...

The approval for the first-line treatment of esophageal squamous cell carcinoma comes shortly after a label expansion for the ...

When you have HER2-negative advanced (metastatic ... Pembrolizumab (Keytruda) stops the checkpoint protein PD-1 from attaching to another protein, PD-L1, that sits on the surface of T cells.

Striking study results last year indicated a new type of medicine may improve on Merck’s immunotherapy, spurring a wave of ...

AstraZeneca and Daiichi Sankyo's Enhertu has become the first HER2-directed drug to mount a patient survival benefit in a ...

The updated guidelines note that patients with stage IV NSCLC who have EGFR exon 19 deletions or exon 21 L858R substitutions can receive osimertinib plus platinum doublet chemotherapy or amivantamab ...

Patients with PD-L1-positive tumors lived more than seven months longer on Tevimbra added to chemotherapy compared to just chemo.

AnaptysBio may have ended last year on a low, but 2025 is looking up with the news that its PD-1 agonist rosnilimab has hit the goals of a phase 2 rheumatoid arthritis (RA) trial. The phase 2b ...

David Zhen, MD, discussed the relevance of nivolumab in the upper gastrointestinal cancer population. In an interview with ...

Tislelizumab plus chemotherapy received FDA approval as a frontline therapy for individuals with unresectable or metastatic ...

Tharimmune (THAR) announced the expansion of its product pipeline with HS1940, a dual-target multispecific biologic engineered to bind to both ...